Clinical Trials: Ethics Committee / IRB Audit Findings

IRB Audit Findings: Common Issues in Clinical Trials

Posted on digi By digi

Institutional Review Boards (IRBs) or Ethics Committees (ECs) play a critical role in protecting the rights, safety, and welfare of participants in clinical trials. Regulatory agencies such as the FDA, EMA, and MHRA require IRBs to ensure that trials comply with ethical and scientific standards under ICH GCP. Despite their importance, IRBs frequently appear in regulatory audit reports with recurring deficiencies.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Delayed Protocol Amendment Approvals Reported as Audit Findings

Posted on digi By digi

Protocol amendments are a routine part of clinical trial conduct, addressing safety issues, operational adjustments, or regulatory feedback. However, these amendments must be reviewed and approved by Institutional Review Boards (IRBs) or Ethics Committees (ECs) before implementation. Delays in approvals are a frequent cause of audit findings, as they can result in protocol deviations, non-compliance with ICH GCP, and increased risks to participants.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Incomplete SAE Reporting to IRBs Noted During Inspections

Posted on digi By digi

Serious Adverse Events (SAEs) represent critical safety data that must be reviewed by Institutional Review Boards (IRBs) or Ethics Committees (ECs) to safeguard participant welfare. Regulatory agencies including the FDA, EMA, and MHRA mandate complete and timely reporting of SAEs to IRBs in compliance with ICH GCP. Failure to ensure proper reporting is one of the most frequently cited audit findings in clinical trials.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

IRB Oversight Failures in Multicenter Clinical Trials

Posted on digi By digi

Multicenter clinical trials involve multiple investigator sites across regions or countries, increasing complexity in regulatory oversight and ethical review. Institutional Review Boards (IRBs) or Ethics Committees (ECs) are responsible for ensuring participant safety and ethical compliance at each site. Regulatory agencies including the FDA, EMA, and MHRA consistently cite IRB oversight failures in multicenter trials as recurring audit findings.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Missing Continuing Review Approvals in IRB Audit Reports

Posted on digi By digi

Continuing review approvals are a cornerstone of Institutional Review Board (IRB) or Ethics Committee (EC) oversight. They ensure that ongoing clinical trials remain ethically justified, scientifically valid, and safe for participants. Regulatory agencies such as the FDA, EMA, and MHRA require IRBs to conduct and document continuing reviews at least annually, or more frequently if necessary. Missing continuing review approvals are a recurring audit finding that undermines both participant protection and regulatory compliance.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Conflict of Interest Gaps in IRB Documentation Audit Findings

Posted on digi By digi

Conflict of Interest (COI) management is central to ensuring that Institutional Review Boards (IRBs) or Ethics Committees (ECs) act independently and prioritize participant safety. Regulatory bodies such as the FDA, EMA, and MHRA require IRBs to have documented processes for identifying, disclosing, and managing COIs. Audit reports, however, frequently highlight gaps in COI documentation, raising concerns about impartiality in protocol review and approval.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Audit Observations on Independent Ethics Committee Compliance

Posted on digi By digi

Independent Ethics Committees (IECs) serve the same essential role as Institutional Review Boards (IRBs): safeguarding the rights, safety, and well-being of clinical trial participants. Regulatory agencies such as the FDA, EMA, and MHRA require IECs to function independently, transparently, and in line with ICH GCP guidelines. Despite these mandates, audits consistently reveal compliance gaps within IECs, ranging from incomplete approvals to missing documentation.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Delays in IRB Review of Updated Informed Consent Forms

Posted on digi By digi

Informed Consent Forms (ICFs) are critical documents that ensure participants are fully informed about trial risks, benefits, and procedures. When protocols are amended or new safety information arises, updated ICFs must be promptly reviewed and approved by Institutional Review Boards (IRBs) or Ethics Committees (ECs) before use. Regulatory authorities such as the FDA, EMA, and MHRA expect strict timelines for ICF review and approval.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

Missing IRB Meeting Minutes in TMF Audit Findings

Posted on digi By digi

Institutional Review Board (IRB) or Ethics Committee (EC) meeting minutes are critical documents that demonstrate ethical oversight, review of study protocols, and decision-making processes. Regulatory agencies including the FDA, EMA, and MHRA require meeting minutes to be detailed, contemporaneous, and archived in the Trial Master File (TMF). Missing or incomplete minutes are a frequent audit finding that raises concerns about transparency, compliance, and oversight.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings

IRB Training and Oversight Deficiencies Highlighted in Audits

Posted on digi By digi

Institutional Review Boards (IRBs) or Ethics Committees (ECs) are entrusted with ensuring that clinical trials adhere to ethical principles and regulatory standards. For IRBs to perform effectively, members must be adequately trained on ICH GCP, local regulations, and ethical responsibilities. Regulatory agencies including the FDA, EMA, and MHRA frequently identify training and oversight deficiencies during audits, reflecting systemic weaknesses in governance and compliance.

Click to read the full article.

Ethics Committee / IRB Audit Findings, Regulatory Audit Findings